Experimental autoimmune neuritis (EAN) is an autoantigen-specific T-cell-mediated disease model for human demyelinating inflammatory disease of the peripheral nervous system. Erythropoietin (EPO) has been known to promote EAN recovery but its haematopoiesis stimulating effects may limit its clinic application. Here we investigated the effects and potential mechanisms of an EPO-derived nonerythropoietic peptide, ARA 290, in EAN. Exogenous ARA 290 intervention greatly improved EAN recovery, improved nerve regeneration and remyelination, and suppressed nerve inflammation. Furthermore, haematopoiesis was not induced by ARA 290 during EAN treatment. ARA 290 intervention suppressed lymphocyte proliferation and altered helper T cell differentiation by inducing increase of Foxp3+/CD4+ regulatory T cells and IL-4+/CD4+ Th2 cells and decrease of IFN-γ+/CD4+ Th1 cells in EAN. In addition, ARA 290 inhibited inflammatory macrophage activation and promoted its phagocytic activity. In vitro, ARA 290 was shown to promote Schwann cell proliferation and inhibit its inflammatory activation. In summary, our data demonstrated that ARA 290 could effectively suppress EAN by attenuating inflammation and exerting direct cell protection, indicating that ARA 290 could be a potent candidate for treatment of autoimmune neuropathies.
References
[1]
Hughes RA (2002) Systematic reviews of treatment for inflammatory demyelinating neuropathy. J Anat 200: 331–339. doi: 10.1046/j.1469-7580.2002.00041.x
[2]
Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, et al. (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30: 131–156. doi: 10.1002/mus.20076
Meyer zu Horste G, Hu W, Hartung HP, Lehmann HC, Kieseier BC (2008) The immunocompetence of Schwann cells. Muscle Nerve 37: 3–13. doi: 10.1002/mus.20893
[7]
Glaspy JA (2009) Erythropoietin in cancer patients. Annu Rev Med 60: 181–192. doi: 10.1146/annurev.med.60.050307.110718
[8]
Maiese K, Chong ZZ, Li F, Shang YC (2008) Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Prog Neurobiol 85: 194–213. doi: 10.1016/j.pneurobio.2008.02.002
[9]
Chateauvieux S, Grigorakaki C, Morceau F, Dicato M, Diederich M (2011) Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol 82: 1291–1303. doi: 10.1016/j.bcp.2011.06.045
[10]
Farrell F, Lee A (2004) The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9 Suppl 518–30. doi: 10.1634/theoncologist.9-90005-18
[11]
Brines M, Cerami A (2005) Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6: 484–494. doi: 10.1038/nrn1687
[12]
Nairz M, Sonnweber T, Schroll A, Theurl I, Weiss G (2012) The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect 14: 238–246. doi: 10.1016/j.micinf.2011.10.005
[13]
Xanthos T, Vasileiou PV, Kakavas S, Syggelou A, Iacovidou N (2011) The potential role of erythropoietin as a pleiotropic agent in post-cardiac arrest syndrome. Curr Pharm Des 17: 1517–1529. doi: 10.2174/138161211796197115
[14]
Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, et al. (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 101: 14907–14912. doi: 10.1073/pnas.0406491101
[15]
Henke M, Laszig R, Rube C, Schafer U, Haase KD, et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255–1260. doi: 10.1016/s0140-6736(03)14567-9
[16]
Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM (2004) The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 27: 185–190. doi: 10.1016/j.jpainsymman.2003.06.010
[17]
Bohlius J, Weingart O, Trelle S, Engert A (2006) Cancer-related anemia and recombinant human erythropoietin–an updated overview. Nat Clin Pract Oncol 3: 152–164. doi: 10.1038/ncponc0451
[18]
Shin T, Ahn M, Moon C, Kim S (2012) Erythropoietin and autoimmune neuroinflammation: lessons from experimental autoimmune encephalomyelitis and experimental autoimmune neuritis. Anat Cell Biol 45: 215–220. doi: 10.5115/acb.2012.45.4.215
[19]
Mausberg AK, Meyer Zu Horste G, Dehmel T, Stettner M, Lehmann HC, et al. (2011) Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-beta in macrophages. PLoS One 6: e26280. doi: 10.1371/journal.pone.0026280
[20]
Zhang G, Lehmann HC, Bogdanova N, Gao T, Zhang J, et al. (2011) Erythropoietin enhances nerve repair in anti-ganglioside antibody-mediated models of immune neuropathy. PLoS One 6: e27067. doi: 10.1371/journal.pone.0027067
[21]
Brines M, Patel NS, Villa P, Brines C, Mennini T, et al. (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 105: 10925–10930. doi: 10.1073/pnas.0805594105
[22]
Enders U, Lobb R, Pepinsky RB, Hartung HP, Toyka KV, et al. (1998) The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis of the Lewis rat. Brain 121 (Pt 7): 1257–1266. doi: 10.1093/brain/121.7.1257
[23]
Kiefer R, Kieseier BC, Stoll G, Hartung HP (2001) The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 64: 109–127. doi: 10.1016/s0301-0082(00)00060-5
[24]
Bohr S, Patel SJ, Shen K, Vitalo AG, Brines M, et al. (2013) Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns. Proc Natl Acad Sci U S A 110: 3513–3518. doi: 10.1073/pnas.1214099110
[25]
van Rijt WG, Nieuwenhuijs-Moeke GJ, van Goor H, Jespersen B, Ottens PJ, et al. (2013) ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury. J Transl Med 11: 9. doi: 10.1186/1479-5876-11-9
[26]
Swartjes M, Morariu A, Niesters M, Brines M, Cerami A, et al. (2011) ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and beta-common receptor knockout mice. Anesthesiology 115: 1084–1092. doi: 10.1097/aln.0b013e31822fcefd
[27]
Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, et al. (2012) Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 18: 1430–1436.
[28]
Schabet M, Whitaker JN, Schott K, Stevens A, Zurn A, et al. (1991) The use of protease inhibitors in experimental allergic neuritis. J Neuroimmunol 31: 265–272. doi: 10.1016/0165-5728(91)90048-c
[29]
Craggs RI, King RH, Thomas PK (1984) The effect of suppression of macrophage activity on the development of experimental allergic neuritis. Acta Neuropathol 62: 316–323. doi: 10.1007/bf00687614
[30]
Maurer M, Toyka KV, Gold R (2002) Cellular immunity in inflammatory autoimmune neuropathies. Rev Neurol (Paris) 158: S7–15.
[31]
Bettelli E, Korn T, Oukka M, Kuchroo VK (2008) Induction and effector functions of T(H)17 cells. Nature 453: 1051–1057. doi: 10.1038/nature07036
[32]
Dong C (2008) TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8: 337–348. doi: 10.1038/nri2295
